Korro Bio (NASDAQ:KRRO) Major Shareholder Edward Mathers Acquires 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Edward Mathers bought 207,100 shares of the stock in a transaction dated Tuesday, March 10th. The stock was purchased at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the acquisition, the insider directly owned 1,297,893 shares in the company, valued at approximately $14,419,591.23. The trade was a 18.99% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Korro Bio Stock Up 12.6%

Korro Bio stock traded up $1.45 during midday trading on Friday, reaching $12.95. The stock had a trading volume of 552,892 shares, compared to its average volume of 237,193. The firm has a market cap of $121.97 million, a price-to-earnings ratio of -1.38 and a beta of 2.98. Korro Bio, Inc. has a 52-week low of $5.20 and a 52-week high of $55.89. The company has a fifty day moving average of $10.90 and a 200 day moving average of $20.23.

Korro Bio (NASDAQ:KRRO) last released its earnings results on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). Korro Bio had a negative net margin of 1,199.53% and a negative return on equity of 68.87%. The business had revenue of $1.29 million for the quarter, compared to the consensus estimate of $0.43 million. Equities research analysts predict that Korro Bio, Inc. will post -9.52 EPS for the current year.

Key Stories Impacting Korro Bio

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA?17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major?holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO?121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha?1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near?term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return?on?equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

Wall Street Analyst Weigh In

KRRO has been the topic of a number of research analyst reports. Cantor Fitzgerald upped their price target on shares of Korro Bio from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday. Chardan Capital upgraded shares of Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Thursday, January 29th. HC Wainwright reaffirmed a “neutral” rating on shares of Korro Bio in a research report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, January 9th. Finally, William Blair raised Korro Bio from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Hedge Funds Weigh In On Korro Bio

Several institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in Korro Bio in the third quarter worth approximately $39,000. Wells Fargo & Company MN boosted its position in Korro Bio by 45.5% during the 4th quarter. Wells Fargo & Company MN now owns 7,522 shares of the company’s stock valued at $60,000 after acquiring an additional 2,352 shares in the last quarter. Guggenheim Capital LLC purchased a new position in shares of Korro Bio in the 4th quarter valued at $84,000. Jain Global LLC bought a new position in shares of Korro Bio in the 4th quarter worth $85,000. Finally, Deutsche Bank AG raised its position in shares of Korro Bio by 241.9% in the 4th quarter. Deutsche Bank AG now owns 12,758 shares of the company’s stock worth $102,000 after acquiring an additional 9,027 shares in the last quarter. 13.18% of the stock is owned by hedge funds and other institutional investors.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.